Sugi Predict

Sugi Predict / Compounds / SCHEMBL744361

SCHEMBL744361

SCHEMBL744361

[c]1csc(N2CCOCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ AR P10275 11/20 0.41
▸ NPC1 O15118 6/20 0.41
▸ RAB9A P51151 6/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ALOX15 P16050 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6598067 0.77 TDP1 (0.41) LMNANPC1RAB9ASMN1; SMN2MAPT
SCHEMBL418589 0.77 MAPT (0.45) LMNANPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4717508 0.73 LGMN (0.44) LMNAARNPC1RAB9ASMN1; SMN2
SCHEMBL415277 0.67 KMT2A (0.53) LMNANPC1RAB9AMAPTMEN1
SCHEMBL6596263 0.67 POLB (0.44) LMNARAB9ASMN1; SMN2MAPTMEN1
SCHEMBL1932306 0.67 NPC1 (0.53) LMNAARNPC1RAB9ASMN1; SMN2
SCHEMBL4468758 0.67 LMNA (0.49) LMNAARNPC1RAB9ASMN1; SMN2
SCHEMBL17266277 0.65 AR (0.61) LMNAARNPC1RAB9ASMN1; SMN2
SCHEMBL746153 0.65 NPC1 (0.40) LMNAARNPC1RAB9ASMN1; SMN2
SCHEMBL24375919 0.64 LMNA (0.58) LMNAARNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10842803-B2 Imidazopyridines Syk inhibitors Kronos Bio, Inc. (US) 2020-11-24 — — US claimed
US-20190117679-A1 IMIDAZOPYRIDINES SYK INHIBITORS Kronos Bio, Inc. 2019-04-25 — — US claimed
EP-2545052-B1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2014-11-12 — — EP claimed
US-20140148430-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-05-29 — — US claimed
US-20130210802-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc (US) 2013-08-15 — — US claimed
US-20130116230-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2013-05-09 — — US claimed
US-8362003-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2013-01-29 — — US claimed
EP-2545052-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc. (US) 2013-01-16 — — EP claimed
EP-2431357-A2 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors Incyte Corporation (US) 2012-03-21 — — EP claimed
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION 2011-10-13 — — US claimed
US-20070259925-A1 DPP IV INHIBITORS BOEHRINGER MARKUS 2007-11-08 — — US claimed
EP-1565436-A4 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORP (US) 2007-07-18 — — EP claimed
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors INCYTE HOLDINGS CORPORATION 2006-11-09 — — US claimed
JP-2006516145-A — — 2006-06-22 — — JP claimed
EP-1565436-A2 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2005-08-24 — — EP claimed
US-20050096348-A1 DPP IV inhibitors BOEHRINGER MARKUS (CH) 2005-05-05 — — US claimed
EP-1441719-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-04 — — EP claimed
WO-2004050024-A2 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2004-06-17 — — WO claimed
US-20030130281-A1 DPP IV inhibitors HOFFMAN-LA ROCHE INC. 2003-07-10 — — US claimed
WO-2003037327-A1 N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS F. HOFFMANN-LA-ROCHE AG (CH) 2003-05-08 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116230-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CXCR3, CCR5 LMNA 4263/4885AR 687/4885NPC1 4125/4885
US-20190117679-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 LMNA 4495/4885AR 4750/4885NPC1 3797/4885
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors CCR2, CXCR3, CCR5 LMNA 3873/4885AR 579/4885NPC1 4033/4885
US-20130210802-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 LMNA 4506/4885AR 4750/4885NPC1 3947/4885
US-20140148430-A1 IMIDAZOPYRIDINES SYK INHIBITORS SYK, BTK, ZAP70 LMNA 4506/4885AR 4750/4885NPC1 3947/4885
US-10842803-B2 Imidazopyridines Syk inhibitors SYK, BTK, ZAP70 LMNA 4495/4885AR 4750/4885NPC1 3797/4885
US-20070259925-A1 DPP IV INHIBITORS DPP4, DPP3, DPP7 LMNA 4657/4885AR 2249/4885NPC1 801/4885
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CXCR3, CCR5 LMNA 4263/4885AR 687/4885NPC1 4125/4885
US-20030130281-A1 DPP IV inhibitors DPP4, DPP3, DPP7 LMNA 4737/4885AR 2446/4885NPC1 591/4885
US-20050096348-A1 DPP IV inhibitors DPP4, DPP3, DPP7 LMNA 4657/4885AR 2249/4885NPC1 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.